XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2025
Dec. 31, 2024
Assets    
Debt securities, available for sale, at fair value, net of allowance for credit losses of $0.0 (2024 - $1.1) (cost - $4,617.0; 2024 - $5,143.8) $ 4,635.2 $ 5,131.0
Debt securities, trading, at fair value (cost - $140.9; 2024 - $187.3) 117.6 162.2
Short-term investments, at fair value (cost - $48.2; 2024 - $95.3) 48.2 95.8
Other long-term investments, at fair value (cost - $437.9; 2024 - $438.2) (includes related party investments at fair value of $220.1 (2024 - $217.2)) 317.7 316.5
Total investments 5,118.7 5,705.5
Cash and cash equivalents 740.3 682.0
Restricted cash and cash equivalents 184.9 212.6
Due from brokers 18.8 11.2
Interest and dividends receivable 42.1 44.0
Insurance and reinsurance balances receivable, net 2,240.8 2,054.4
Deferred acquisition costs, net 369.3 327.5
Unearned premiums ceded 514.3 463.9
Loss and loss adjustment expenses recoverable, net 2,335.7 2,315.3
Deferred tax asset 293.3 297.0
Intangible assets 137.9 140.8
Other assets 284.4 270.7
Total assets 12,280.5 12,524.9
Liabilities    
Loss and loss adjustment expense reserves 5,762.6 5,653.9
Unearned premium reserves 1,816.8 1,639.2
Reinsurance balances payable 1,707.5 1,781.6
Deposit liabilities 15.6 17.4
Deferred gain on retroactive reinsurance 6.6 8.5
Debt 663.5 639.1
Due to brokers 6.6 18.0
Deferred tax liability 94.2 76.2
Share repurchase liability 0.0 483.0
Other liabilities 180.4 269.2
Total liabilities 10,253.8 10,586.1
Commitments and contingent liabilities
Shareholders’ equity    
Common shares (issued and outstanding: 116,020,526; 2024 - 116,429,057) 11.6 11.6
Additional paid-in capital 944.7 945.0
Retained earnings 842.5 784.9
Accumulated other comprehensive income (loss), net of tax 26.4 (4.1)
Shareholders’ equity attributable to SiriusPoint shareholders 2,025.2 1,937.4
Noncontrolling interests 1.5 1.4
Total shareholders’ equity 2,026.7 1,938.8
Total liabilities, noncontrolling interests and shareholders’ equity 12,280.5 12,524.9
Series B preference shares    
Shareholders’ equity    
Series B preference shares (par value $0.10; authorized and issued: 8,000,000) $ 200.0 $ 200.0